NEKTAR THERAPEUTICS
Company Stats
- Market Cap
- $2.1B
- as of Sep 30, 2026
- Shares Outstanding
- 34.1M
- Free Float
- 27.9%
Income Statement
- Revenue
- $55.2M
- Operating Income
- -$140.1M
- Net Income
- -$164.1M
- EBITDA
- -$139.1M
- Non-cash Impairment
- $4.4M
- Revenue Growth, 3Y
- -15.7%
- FCF Margin, 3Y Avg
- -257.5%
- FCF Margin, Worst Year
- -377.8%
Cash Flow
- Free Cash Flow
- -$208.7M
- FCF Yield
- -10.1%
- Owner FCF Yield
- -10.7%
Balance Sheet
- Cash & Equivalents
- $15.1M
Returns & Capital
- Buyback Yield, 3Y Avg
- 0.0%
- SBC, 3Y Avg
- $22.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $55.2M | -$208.7M | -377.8% |
| FY2024 | $98.4M | -$177.2M | -180.0% |
| FY2023 | $90.1M | -$193.5M | -214.7% |
| FY2022 | $92.1M | -$309.7M | -336.4% |
| FY2021 | $101.9M | -$427.6M | -419.6% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 25, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges